BR0014861A - Viral particles with exogenous internal epitopes - Google Patents

Viral particles with exogenous internal epitopes

Info

Publication number
BR0014861A
BR0014861A BR0014861-0A BR0014861A BR0014861A BR 0014861 A BR0014861 A BR 0014861A BR 0014861 A BR0014861 A BR 0014861A BR 0014861 A BR0014861 A BR 0014861A
Authority
BR
Brazil
Prior art keywords
viral particles
expression
viruses
exogenous
epitopes
Prior art date
Application number
BR0014861-0A
Other languages
Portuguese (pt)
Inventor
Koen Hellendoorn
Tim Jones
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of BR0014861A publication Critical patent/BR0014861A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
    • C12N15/8203—Virus mediated transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"PARTìCULAS VIRAIS COM EPìTOPOS INTERNOS EXóGENOS". A presente invenção refere-se à expressão de peptídeos em partículas virais e mais particularmente à expressão de peptídeos no interior do capsídeo viral. São descritos métodos para modificar os vírus de forma que os epítopos exógenos são expressos no interior do capsídeo viral. Os vírus que podem ser modificados incluem os vírus de RNA de filamento (+), especialmente os vírus vegetais de RNA de filamento (+) tal como o vírus mosáico do feijão-de-corda. A expressão interna é especialmente útil para a expressão de epítopos hidrofóbicos. As partículas virais modificadas também encontram uso como vacinas e como tais são capazes de ativar uma resposta imunológica."VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITOS". The present invention relates to the expression of peptides in viral particles and more particularly to the expression of peptides within the viral capsid. Methods for modifying viruses are described so that exogenous epitopes are expressed within the viral capsid. Viruses that can be modified include filament RNA viruses (+), especially vegetable filament RNA viruses (+) such as the arabica bean virus. Internal expression is especially useful for the expression of hydrophobic epitopes. The modified viral particles also find use as vaccines and as such are able to activate an immune response.

BR0014861-0A 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes BR0014861A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924352.9A GB9924352D0 (en) 1999-10-14 1999-10-14 Methods,compositions and applications relating to the generation of novel plant viral particles
PCT/US2000/028430 WO2001027282A1 (en) 1999-10-14 2000-10-13 Plant virus particles with exogenous internal eitopes

Publications (1)

Publication Number Publication Date
BR0014861A true BR0014861A (en) 2002-07-16

Family

ID=10862753

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014861-0A BR0014861A (en) 1999-10-14 2000-10-13 Viral particles with exogenous internal epitopes

Country Status (16)

Country Link
EP (1) EP1235910A1 (en)
JP (1) JP2003534771A (en)
KR (1) KR100880477B1 (en)
CN (2) CN101591647A (en)
AR (1) AR026066A1 (en)
AU (1) AU785020B2 (en)
BR (1) BR0014861A (en)
CA (1) CA2387626A1 (en)
CO (1) CO5280142A1 (en)
CZ (1) CZ20021303A3 (en)
GB (1) GB9924352D0 (en)
IL (1) IL149077A0 (en)
MX (1) MXPA02003789A (en)
PL (1) PL354933A1 (en)
WO (1) WO2001027282A1 (en)
ZA (1) ZA200202815B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1409551A4 (en) * 2001-06-21 2004-10-13 Uab Research Foundation Chimeric capsid proteins and uses thereof
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
PT1523329E (en) 2002-07-05 2013-10-08 Folia Biotech Inc Adjuvant viral particle
WO2006041933A2 (en) 2004-10-05 2006-04-20 Diversa Corporation Improved vaccines
EP1885394A4 (en) * 2005-06-01 2009-10-21 Dow Global Technologies Inc Production of multivalent virus like particles
CA2615658A1 (en) * 2005-07-19 2007-01-25 Dow Global Technolgies Inc. Recombinant flu vaccines
CN101784655A (en) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles
WO2013003353A2 (en) * 2011-06-30 2013-01-03 Stc.Unm Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9108386D0 (en) * 1991-04-19 1991-06-05 Agricultural Genetics Co Modified plant viruses as vectors
GB9712282D0 (en) * 1997-06-12 1997-08-13 Innes John Centre Innov Ltd Epitope presentation system

Also Published As

Publication number Publication date
CA2387626A1 (en) 2001-04-19
CN1471580A (en) 2004-01-28
CZ20021303A3 (en) 2002-10-16
AR026066A1 (en) 2002-12-26
AU785020B2 (en) 2006-08-24
IL149077A0 (en) 2002-11-10
AU1085201A (en) 2001-04-23
PL354933A1 (en) 2004-03-22
MXPA02003789A (en) 2002-09-30
WO2001027282A1 (en) 2001-04-19
EP1235910A1 (en) 2002-09-04
WO2001027282A8 (en) 2001-08-16
CO5280142A1 (en) 2003-05-30
CN101591647A (en) 2009-12-02
GB9924352D0 (en) 1999-12-15
JP2003534771A (en) 2003-11-25
KR100880477B1 (en) 2009-01-28
ZA200202815B (en) 2003-08-27
KR20020040868A (en) 2002-05-30

Similar Documents

Publication Publication Date Title
PT1294893E (en) MODIFICATION OF HEPATITIS B NUCLEAR ANTIGEN
BR0014171A (en) Composition
EA200900784A1 (en) VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS
HU9500571D0 (en) Retro-, inverso-, and retro-inverso synthetic peptide analogues
IL153290A0 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
ES2035818T3 (en) DELETION MUTANTS OF TIMIDIN-KINASA FROM HERPES BOVINE-1 VIRUSES, VACCINES AGAINST INFECTIOUS BOVINE RHINOTRAQUEITIS AND METHODS FOR THEIR PRODUCTION AND USE.
EA200801756A1 (en) ANTIGRIPOPOSIC VACCINES CONTAINING HEMAGGLUTININ AND PROTEINS OF MATRIX
HUT69803A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
BR9908599A (en) Combined vaccine compositions
MXPA02002483A (en) Vaccine against hbv and hpv.
DE69332831D1 (en) RECOMBINANT PIGROCK VIRUS
BR0014861A (en) Viral particles with exogenous internal epitopes
NZ518999A (en) Vaccine compositions
TW200503752A (en) HCV vaccines
SG49876A1 (en) Recombinant avipox virus, the culture of cells infected with this virus and vaccines for poultry derived from this virus
BR0015740A (en) Membrane virus host range mutations and their use as vaccine substrates
ES2061603T3 (en) VIRAL MUTANTS OF INFECTIOUS BOVINE RHINOTRACHEITIS, VACCINES THAT CONTAIN THEM, METHODS FOR THE PRODUCTION OF THE SAME AND METHODS FOR THE USE OF THE SAME.
OA09653A (en) Rubella peptides
PT100460A (en) PARTICLES DERIVED FROM HERPES VIRUSES AND VACCINES THAT CONTAIN THEM
ATE453708T1 (en) VACCINE AGAINST WEST NILE VIRUS
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
Mordhorst Quantitation of the infectivity for cynomolgus monkeys of egg-grown inclusion conjunctivitis virus. A comparison of the clinical course of the experimental disease, the appearance of inclusion bodies and the regular recovery of the viral agent
Arnon et al. Anti-influenza synthetic vaccine.
ATE126702T1 (en) METHOD FOR PRODUCING VACCINES AGAINST RNA VIRUS.
Hradečná X-ray Inactivation of Lambda Phage: II. Reactivation Processes

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]